St John's wort for depression: A systematic review

Archives of Internal Medicine

Volumn 160, Issue 2, 2000, Pages 152-156

  Gaster, Barak ^a,b   Holroyd, John ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Box 354760 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HYPERICUM PERFORATUM; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; TREATMENT OUTCOME;

EID: 0034707701     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.2.152     Document Type: Review

References (40)

1. National Center for Health Statistics. Ambulatory care visits to physicians' offices, hospital outpatient departments and emergency departments: United States, 1996. Vital Health Stat 13. 1997; No. 134.
2. Lieberman S. Nutriceutical review of St. John's wort (Hypericum perforatum) for the treatment of depression. J Womens Health. 1998;7:177-182.
3. Miller AL. St. John's wort (Hypericum perforatum): clinical effects on depression and other conditions. Altern Med Rev. 1998;3:18-26.
4. St. John's wort. Med Lett Drugs Ther. 1997;39: 107-108.
5. De Smet PA, Nolen WA. St John's wort as an antidepressant. BMJ. 1996;313:241-242.
6. Snow JM. Hypericum perforatum. Protocol J Botanical Med. 1996;2:16-21.
7. Canedy D. Real medicine or medicine sideshow? New York Times. July 23, 1998:C1-2.
8. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients: an overview. Pharmacopsychiatry. 1997;30(suppl 2):72-76.
9. Angst J, Bech P, Boyer P, et al. Consensus on the methodology of clinical trials of antidepressants. Pharmacopsychiatry. 1989;22:3-7.
10. Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S9-S11.
11. Hubner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S12-S14.
12. Hansgen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160, J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S15-S18.
13. Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. Hum Psychopharmacol. 1998;13:163-159.
14. Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S19-S23.
15. Harrer G, Hubner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol. 1994;7 (suppl 1):S24-S28.
16. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry. 1997;30(suppl 2): 77-80.
17. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997;30(suppl 2):81-85.
18. Martinez B, Kasper S, Ruhrmann S. Moller HJ. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol. 1994;7 (suppl1):S29-S33.
19. Mueller BM. St. John's wort for depressive disorders: results of an outpatient study with the hypericum preparation HYP. Adv Ther. 1998;15: 109-116.
20. Ditzler K, Gessner B, Schatten WFH, Willems M. Clinical trials on Neuropas versus placebo in patients with mild to moderate depressive symptoms. Complementary Ther Med. 1994;2:5-13.
21. Kasper S. Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry. 1997;30(suppl 2):89-93.
22. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry. 1997;30(suppl 2):108-112.
23. Teufel-Mayer R, Gleitz J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry. 1997;30(suppl 2):113-116.
24. Muller WE, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychistry, 1997;30(suppl 2):102-107.
25. The Review of Natural Products: St. John 's Wort. St Louis, Mo: Facts and Comparisons; 1997:1-3.
26. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S57-S59.
27. Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S54-S55.
28. Lima MS, Moncrieff J. A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review. Oxford, England: Cochrane Library; 1998.
29. Physicians Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998.
30. Woelk H, Burkard G, Grunwald J. Benefits and risks of the hypericum extract LI 160: drug-monitoring study with 3250 patients. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S34-S38.
31. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry. 1997;30(suppl 2): 94-101.
32. Czekalla J, Gastpar M, Hubner WD, Jager D. The effect of hypericura extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry. 1997; 30(suppl 2):86-88.
33. Gordon JB SSRIs and St. John's wort: possible toxicity [letter]? Am Fam Physician. 1998;57:950-953.
34. United States Pharmacopeia annual report. Helping guide professionals and consumers through the botanical product quagmire; 1997. Available at: http://www.usp.org/pubs/annual.rpt/1997. Accessed November 8, 1998.
35. Monmaney T. Analysis finds label claims often inaccurate Los Angeles Times. August 31, 1998: A10.
36. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313:253-258.
37. National Institutes of Health press release. St. John's wort study launched. Available at: http:// www.nih.gov/news/pr/oct97. Accessed October 6, 1998.
38. FDA determines supplement cholestin to be an unapproved drug [press release]. Rockville, Md: Food and Drug Administration, US Dept of Health and Human Services; May 20, 1998.
39. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-252.
40. Eisenberg DM, Advising patients who seek alternative medical therapies. Ann Intern Med. 1997; 127:61-69.